Onyx nailed an FDA approval today for the multiple myeloma drug Kyprolis (carfilzomib), overcoming the naysayers who were skeptical that the agency would hand out an accelerated OK for a new drug on just mid-stage data drawn from a single-arm study.
Onyx's risky attempt to win an approval for the multiple myeloma drug carfilzomib on the basis of mid-stage data from a single-arm study cleared a major hurdle yesterday evening when an FDA advisory group gave its drug a unanimous thumbs up.
Shares of Onyx ($ONXX) slid 6% this morning on the news that it will have to settle for a standard review of its closely-watched cancer drug carfilzomib after failing to win an accelerated review.
Onyx Pharmaceuticals took another big step forward in its quest to gain an approval for the closely watched multiple myeloma drug carfilzomib, calling a wrap on its NDA as it seeks an accelerated
Onyx's $851 million deal to buy out Proteolix and its potential blockbuster cancer drug is returning some handsome rewards this morning. Ono Pharmaceutical snagged the Japanese rights to the
When Onyx bought out Proteolix last year for $276 million down and up to $575 million in milestones, both sides highlighted the starring role of the cancer drug carfilzomib in the deal. Emeryville,
The American Society of Hematology meeting underway now in New Orleans provided a big stage for Onyx to tout promising new mid-stage data on a cancer therapy acquired last month in its $851 million
Onyx Pharmaceuticals (ONXX) has struck a deal to buy the cancer drug developer Proteolix for $276 million down and up to $575 million more for development and regulatory milestones. Included in the
South San Francisco-based Proteolix has raised $79 million to fund its development of new drugs that target protein degradation pathways in cancer and autoimmune diseases. Money from the third